# Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

> **NCT01210352** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Post Operative Pain

## Interventions

- **DRUG:** oxymorphone HCl

## Key facts

- **NCT ID:** NCT01210352
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-13
- **Primary completion:** 2017-10-06
- **Final completion:** 2017-10-06
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01210352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01210352, "Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01210352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*